Details for Patent: 10,842,751

Which drugs does patent 10,842,751 protect, and when does it expire?

Patent 10,842,751 protects DELSTRIGO and is included in one NDA.

This patent has twenty-three patent family members in twenty countries.

Summary for Patent: 10,842,751

Patent landscape, scope, and claims:

Title:	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Abstract:	The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine. These compositions are useful for the treatment of HIV infection. Also disclosed are processes for making said pharmaceutical compositions.
Inventor(s):	Panmai; Santipharp (Cranford, NJ), Tatavarti; Aditya (Chalfont, PA), Farrington; Andrew M. (Collegeville, PA), Biyyala; Varsha (Somerset, NJ), Allain; Leonardo R. (Lansdale, PA), Nefliu; Marcela (Schwenksville, PA), Klinzing; Gerard R. (Wilmington, DE), Ren; Jie (Chalfont, PA), Lamm; Matthew (Morristown, NJ)
Assignee:	MERCK SHARP & DOHME CORP. (Rahway, NJ)
Application Number:	16/791,398
Patent Claim Types: see list of patent claims	Formulation; Dosage form;

Drugs Protected by US Patent 10,842,751

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Msd Merck Co	DELSTRIGO	doravirine; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	210807-001	Aug 30, 2018		RX	Yes	Yes	10,842,751		Y

International Family Members for US Patent 10,842,751

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016361612
Brazil	112018011085
Canada	3006192